Using the MYO10 mRNA expression ratio to separate the patient groups, we confirmed that LUSC patients with high MYO10 mRNA expression ratio demonstrate reduced overall survival independent of the tumor stage and treatment regimen (P = 0.008, Fig. 5B left), which was not observed in LUAD patients (P = 0.57, Fig. 5B right). This evidence concerns the gene MYO10 and neoplasm.